Proyecto PDC2022-133488-I00 financiado por MCIN/AEI /10.13039/501100011033 y por la Unión Europea Next GenerationEU/ PRTR

LEUCURE PROJECT

New NPM1-targeted drug for acute myeloid leukemia treatment

LEUCURE PROJECT

New NMP1-TARGETED DRUG

Acute myeloid leukemia (AML) is a disease caused by hematological myeloid cancer stem cells (CSCs) with a high rate of mortality and a low 5-year survival rate (around 30%). The most common mutations with more than 50% incidence are FLT3 and NPM1. While FLT3 mutation has targeted therapies such as midostaurin (Rydapt®), no NPM1 inhibitors have been successfully translated yet to the clinical practice. 

LeuCURE (Funded under the Program Prueba de Concepto, PDC2022-133488-I00) aims at establishing the preclinical potential of novel NPM1 inhibitors developed in our laboratory in order to advance toward clinical phases with new drug candidates for AML that can overcome the limitations of the current frontline therapies.

Madrid

Dr. Miguel Gallardo (CNIO and Hospital 12 de Octubre)

Sevilla

Dr. Irene Díaz-Moreno (Universidad de Sevilla, cicCartuja)

Scientific Output

  • NPM1-depending leukemia agents. Patent WO2023052354 (PCT/EP2022/076831)
  • Validation of new drug targets for the treatment of haematological cancers. Thesis in 3 minutes competition. Madrid (Spain), October 2021
  • Cancer-stem-cell phenotype-guided discovery of a microbiota-inspired synthetic compound targeting NPM1 for leukemia. XXXVIII Reunión Bienal de la Real Sociedad Española de Química (RSEQ). Granada (Spain), June 2022
  • Cancer-stem-cell phenotype-guided discovery of a microbiota-inspired synthetic compound targeting NPM1 for leukemia. XVIII Simposio de Jóvenes Investigadores Químicos de la RSEQ. Sevilla (Spain), November 2022
  • Cancer-stem-cell phenotype-guided discovery of a microbiota-inspired synthetic compound targeting NPM1 for leukemia. ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023. Boston (USA), June 2023